Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review

被引：193

作者：

Garnett, Christine E. ^{[1
]}

Beasley, Nhi ^{[2
]}

Bhattaram, V. Atul ^{[1
]}

Jadhav, Pravin R. ^{[1
]}

Madabushi, Rajanikanth

Stockbridge, Norman ^{[2
]}

Tornoe, Christoffer W. ^{[1
]}

Wang, Yaning ^{[1
]}

Zhu, Hao ^{[1
]}

Gobburu, Jogarao V. ^{[1
]}

机构：

[1] US FDA, CDER, OTS, Off Clin Pharmacol, Silver Spring, MD 20903 USA

[2] US FDA, Ctr Drug Evaluat & Res, Div Cardiovasc & Renal Drug Prod, Silver Spring, MD 20903 USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 48卷 / 01期

关键词：

pharmacokinetics; pharmacodynamics; modeling; QT interval; ICH E14;

D O I：

10.1177/0091270007307881

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The criterion for assessing whether a drug prolongs QT as described in the International Conference on Harmonization topic E14 guideline does not explicitly account for individual drug concentrations. The authors' experience with reviewing QT studies indicates that understanding the relationship, if any, between individual drug concentration and QT change provides important additional information to support regulatory decision making. Therefore, regulatory reviews of "thorough QT" studies routinely include a characterization of the concentration-QT relationship. The authors provide examples to illustrate how the concentration-QT relationship has been used to plan and interpret the thorough QT study, to evaluate QT risk for drugs that have no thorough QT studies, to assess QT risk in subpopulations, to make dose adjustments, and to write informative drug labels.

引用

页码：13 / 18

页数：6

共 26 条

[1] Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation [J].

Abernethy, DR ;

Barbey, JT ;

Franc, J ;

Brown, KS ;

Feirrera, I ;

Ford, N ;

Salazar, DE .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :96-103

[2] Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation [J].

Abernethy, DR ;

Wesche, DL ;

Barbey, JT ;

Ohrt, C ;

Mohanty, S ;

Pezzullo, JC ;

Schuster, BG .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (03) :231-237

[3] The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing [J].

Allen, MJ ;

Nichols, DJ ;

Oliver, SD .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (03) :247-253

[4] Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval [J].

Allen, MJ ;

Oliver, SD ;

Newgreen, MW ;

Nichols, DJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (01) :59-65

[5] Effect of arsenic trioxide on QT interval in patients with advanced malignancies [J].

Barbey, JT ;

Pezzullo, JC ;

Soignet, SL .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3609-3615

[6] Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects [J].

Barbey, JT ;

Sale, ME ;

Woosley, RL ;

Shi, J ;

Melikian, AP ;

Hinderling, PH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (01) :91-99

[7]

BEASLEY N, 2004, AAPS ANN M NOV 7 11

[8]

Food and Drug Administration HHS, 2005, Fed Regist, V70, P61134

[9]

GALEAZZI RL, 1976, CLIN PHARMACOL THER, V20, P278

[10]

Gobburu JVS, 2002, INT J CLIN PHARM TH, V40, P281

← 1 2 3 →